Corrigendum to “Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis” [Tuberculosis 108 (January 2018) 186–194]
Mamoru Fujiwara(Otsuka (Japan)), Makoto Matsumoto(Tottori University Hospital), Yongge Liu(Pharmaceutical Product Development (United States)), Masanori Kawasaki(Otsuka (Japan)), Norimitsu Hariguchi(Otsuka (Japan))
Cited by 3
Related Papers
A Toll-like receptor recognizes bacterial DNA
|Nature|2000|6.4k
HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITY
|The Lancet|1986|2.4k
Targeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
|Immunity|1998|2k
Essential role of Stat6 in IL-4 signalling
|Nature|1996|1.6k
Targeted disruption of the mouse <i>Stat3</i> gene leads to early embryonic lethality
|Proceedings of the National Academy of Sciences|1997|1.3k